Stephen Hahn, FDA commissioner (AP Images)

PDU­FA VII: FDA, in­dus­try pre­view their reau­tho­riza­tion wish lists

At its first pub­lic meet­ing in the runup to the reau­tho­riza­tion of the Pre­scrip­tion Drug User Fee Actthe FDA, in­dus­try and oth­er stake­hold­ers on Thurs­day shed light on their goals for what will be the agency’s sev­enth PDU­FA pro­gram.

The meet­ing, held ful­ly vir­tu­al­ly for the first time due to the COVID-19 pan­dem­ic, is the start­ing point for the ne­go­ti­a­tions with in­dus­try and dis­cus­sions with stake­hold­ers that will shape FDA’s new drug re­view pro­gram from FY2023-FY2027.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.